- rix announces a new portfolio company, Pyxis Oncology, with a 5.6% ownership stake
- Series B proceeds will enable Pyxis to advance differentiated antibody-drug conjugate (ADC) and immune oncology programmes to next value inflection point
- Arix Managing Director Christian Schetter will join the Pyxis Board of Directors
LONDON, 30 March 2021: Arix Bioscience plc (“Arix”, LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it has invested in Pyxis Oncology (“Pyxis”), a new portfolio company. As part of the financing, Arix Managing Director Christian Schetter will join the Pyxis Board of Directors.